AbbVie Reports Successful Trial Results for Arthritis Drug

AbbVie (NYSE: ABBV) reported that its new immunology drug Rinvoq (upadacitinib) successfully met primary and secondary endpoints in a registrational trial for treatment of psoriatic arthritis, clearing the way for the company to file a new drug application (NDA) for the indication later this year.